SLC5A2 and Hyperglycemia: Patients in the DPP-4 and SGLT-2 inhibitor groups demonstrated higher baseline inflammation (SII, NLR) and poorer glycemic control, likely reflecting prescription patterns in patients with more advanced disease or treatment-refractory hyperglycemia.